SMO and chronic myelogenous leukemia, BCR-ABL1 positive: A second trial examined the safety and efficacy of combining the TKI nilotinib and SMO inhibitor erismodegib/sonidegib (LDE225; Novartis) in a phase 1b clinical trial that included 11 CML-CP patients who were resistant, intolerant, or sub-optimally responding to one prior TKI, excluding nilotinib [30].